U.S. Pharmacogenomics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025

Description

The U.S. pharmacogenomics market was valued at USD 3.4 billion in 2024 and is expected to expand at a CAGR of 10.4% between 2025 and 2032, reaching USD 7.3 billion by 2032. This rapid growth is driven by increasing adoption of personalized medicine, rising prevalence of chronic diseases, and growing demand for precision therapies tailored to individual genetic profiles. Technological advancements in genomic sequencing and bioinformatics are enabling faster, more accurate drug response predictions, significantly boosting the market.

Supportive government initiatives and favorable regulatory frameworks promoting research and development are further propelling the market. Increasing awareness among healthcare professionals and patients about the benefits of pharmacogenomic testing is enhancing market penetration. These factors collectively create a dynamic environment for growth and innovation in the U.S. pharmacogenomics market.

Key Insights

The market is segmented by product into pharmacogenomic testing kits, reagents & consumables, and services, with testing kits holding a significant share due to rising demand for accurate diagnostics.

By application, oncology leads the market, driven by the need for targeted cancer therapies, followed by cardiovascular and neurological disorders.

The research organizations dominate end-use due to the integration of pharmacogenomic testing into routine clinical practice.

California, Massachusetts, and New York are key regional markets, supported by strong healthcare infrastructure and presence of major biotech firms.

Technological innovations such as next-generation sequencing (NGS), microarray technology, and CRISPR-based gene editing are shaping market growth.

Leading players like Thermo Fisher Scientific, Illumina Inc., and Roche Diagnostics focus on strategic collaborations and product innovation to expand their market presence.

Increasing investments in pharmacogenomics research and growing adoption of companion diagnostics in clinical trials offer substantial growth opportunities.

Awareness campaigns and educational programs aimed at healthcare providers are facilitating wider acceptance and use of pharmacogenomic testing.

Regulatory support and reimbursement policies are gradually improving, making pharmacogenomic tests more accessible and affordable.

Product Code: 13432

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market Size Breakdown, by Service
- 1.4.2. Market Size Breakdown, by Applications
- 1.4.3. Market Size Breakdown, by End User
1.5. Market Data Reporting Unit
- 1.5.1. Revenue
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence Database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Industry Background
5.2. Market Dynamics
- 5.2.1. Trends
- 5.2.2. Drivers
- 5.2.3. Restraints/Challenges
- 5.2.4. Emerging Economies and Key Opportunities
- 5.2.5. Impact Analysis of Drivers/Restraints
5.3. Impact of COVID-19
5.4. Sociopolitical Impact
5.5. Porter's Five Forces Analysis
- 5.5.1. Bargaining Power of Buyers
- 5.5.2. Bargaining Power of Suppliers
- 5.5.3. Threat of New Entrants
- 5.5.4. Intensity of Rivalry
- 5.5.5. Threat of Substitutes
5.6. Innovation and Technology Trends
5.7. Economic and Regulatory Impact
5.8. Market Entry Strategies

Chapter 6. Competitive Landscape

6.1. List of Market Players and their Offerings
6.2. Market Share of Key Players (2024)
6.3. Competitive Benchmarking of Key Players
6.4. Product Benchmarking of Key Players
6.5. Recent Strategic Developments by Key Players
6.6. Company Leadership Matrix

Chapter 7. U.S. Market

7.1. Overview
7.2. Market Revenue, by Service (2019-2032)
7.3. Market Revenue, by Applications (2019-2032)
7.4. Market Revenue, by End User (2019-2032)
7.5. Market Revenue, by Country (2019-2032)

Chapter 8. Northeast Market

8.1. Overview
8.2. Economic Indicators
8.3. Demographics and Population Insights
8.4. Regional Hotspots
8.5. Growth Drivers
8.6. Challenges and Barriers
8.7. Competitive Strategies
8.8. Emerging Players
8.9. Import/Export Policies
8.10. Compliance Requirements
8.11. Emerging Investment Areas
8.12. Major Ongoing Projects
8.13. Market Size and Forecast
- 8.13.1. Market Revenue, by Service (2019-2032)
- 8.13.2. Market Revenue, by Applications (2019-2032)
- 8.13.3. Market Revenue, by End User (2019-2032)

Chapter 9. Midwest Market

9.1. Overview
9.2. Economic Indicators
9.3. Demographics and Population Insights
9.4. Regional Hotspots
9.5. Growth Drivers
9.6. Challenges and Barriers
9.7. Competitive Strategies
9.8. Emerging Players
9.9. Import/Export Policies
9.10. Compliance Requirements
9.11. Emerging Investment Areas
9.12. Major Ongoing Projects
9.13. Market Size and Forecast
- 9.13.1. Market Revenue, by Service (2019-2032)
- 9.13.2. Market Revenue, by Applications (2019-2032)
- 9.13.3. Market Revenue, by End User (2019-2032)

Chapter 10. West Market

10.1. Overview
10.2. Economic Indicators
10.3. Demographics and Population Insights
10.4. Regional Hotspots
10.5. Growth Drivers
10.6. Challenges and Barriers
10.7. Competitive Strategies
10.8. Emerging Players
10.9. Import/Export Policies
10.10. Compliance Requirements
10.11. Emerging Investment Areas
10.12. Major Ongoing Projects
10.13. Market Size and Forecast
- 10.13.1. Market Revenue, by Service (2019-2032)
- 10.13.2. Market Revenue, by Applications (2019-2032)
- 10.13.3. Market Revenue, by End User (2019-2032)

Chapter 11. South Market

11.1. Overview
11.2. Economic Indicators
11.3. Demographics and Population Insights
11.4. Regional Hotspots
11.5. Growth Drivers
11.6. Challenges and Barriers
11.7. Competitive Strategies
11.8. Emerging Players
11.9. Import/Export Policies
11.10. Compliance Requirements
11.11. Emerging Investment Areas
11.12. Major Ongoing Projects
11.13. Market Size and Forecast
- 11.13.1. Market Revenue, by Service (2019-2032)
- 11.13.2. Market Revenue, by Applications (2019-2032)
- 11.13.3. Market Revenue, by End User (2019-2032)

Chapter 12. Company Profiles

Chapter 13. Appendix

13.1. Sources and References
13.2. Related Reports

U.S. Pharmacogenomics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)